Screener
4D Molecular Therapeutics FDMT Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -230.2%+667,424pp | -220.1%+883,806pp | -204.5%+507,474pp | -191,982.5%+275,729pp | -667,654.5%-667,006pp | |
| Returns | ||||||
| Return on invested capital | -57%-0.5pp | -51.1%+7.0pp | -40.9%+40.9pp | -62.9%+10.4pp | -56.5%-5.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×+0.2× | 0.2×— | 0.2×+0.2× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 8×-0.7× | 9.3×-3.0× | 9.4×-5.5× | 8.4×-8.9× | 8.7×-19.7× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $5.80-22.9% | $6.64-21.2% | $8.73-7.8% | $6.57-33.9% | $7.53-29.3% | |
| Valuation | ||||||
| Market capitalization | $764.58M+88.8% | $475.29M+218% | $428.51M+66.4% | $405.84M-32.1% | $185.3M-84.0% | |
| Price / sales | 8.3×-3,366× | 5.4×-6,497× | 5×-6,954× | 3,382×-13,218× | 5,615.1×+5,558× | |
| Price / book | 1.9×+0.8× | 1.1×+0.7× | 0.8×+0.3× | 1.1×0.0× | 0.4×-1.5× |
FAQ
- Where do 4D Molecular Therapeutics's ratios come from?
- Every ratio is computed from 4D Molecular Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
